As a top off-the-shelf T-cell immunotherapy company, Atara Biotherapeutics Inc (NASDAQ:ATRA) has over the years dedicated itself to the development of novel treatments to assist the various patients struggling with cancer, autoimmune and viral diseases. It was today that it moved ahead to make the announcement regarding its fourth quarter and full year financial results. It was in the same line that it moved ahaed to also unveil its recent operational highlights.
The Chief Executive Officer and President of Atara Biotherapeutics Isaac Ciechanover while addressing several news reporters who sought out to interview him said that as a company they continued to make a major headway in terms of advancing their leadership in T-cell immunotherapy innovation.
He said that they had recently received FDA clearance and that of course meant they could move on with their plan to expand the company’s pioneering multinational clinical study of off-the-shelf ATA188 for persons struggling with multiple sclerosis in the whole of the United States.
Ciechanover took immense pride in the fact that as a company they had managed to accomplish pretty much in the recent years. He said that in the coming 18 months they were determined to revolutionize matters and thus it would be a transformation period.
It is worth noting that the company is planning to make major expansions as well as advance its global commercial capabilities, manufacturing expertise as well as its robust T‑cell immunotherapy pipeline.
The announcement of the submission of an EU conditional marketing authorization application for tab-cel™ and the first tab-cel™ Phase 3 results if all goes according to plan might be made in the first half of 2019.
An official working with the company opined, “ We also have a well-defined strategy to leverage the potential of our platform in other cancer, autoimmune and viral diseases, as well as initiate development of genetically modified off-the-shelf T-cell immunotherapies to transform the lives of patients with serious medical conditions.”
Just like the rest of the progressive companies around the globe, this company has many plans underway which it hopes will help it rise in rakings.